



DT16R PCT/PTO JUN 11 2002 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

LIANG ET AL.

Serial No: 10/070560

Filed: March 8, 2002

For: METHOD OF PRODUCING AND PURIFYING  
ENDOSTATIN PROTEIN

Group Art No: Unassigned

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08A, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of all listed items is enclosed. The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

By: Theodore M. Green  
Reg. No. 41,801

KILPATRICK STOCKTON LLP  
Suite 2800  
1100 Peachtree Road  
Atlanta, Georgia 30309  
(404) 815-6500  
Our Docket: 05213-0551US (43170-258385)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC, 20231, on June 6, 2002.

By:


Theodore M. Green – Reg. No. 41,801

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application No.	10/070560
Filing Date	11/30/2001
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Unassigned


Sheet 1 of 3 Attorney Docket Number 05213-0551US(43170-258385)

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>4</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	1	5,854,205		O'Reilly et al.	12/29/1998	

Examiner  
SignatureDate  
Considered

<sup>4</sup>Unique citation designation number. <sup>5</sup>See attached Kinds of U.S. Patent Documents. <sup>6</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>7</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>8</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>9</sup>Applicant is to place a check mark here if English language translation is attached.



Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if known

				Application No.	10/070560
				Filing Date	03/08/2002
				First Named Inventor	Liang et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	05213-0551US(43170-258385)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Kind Code <sup>5</sup> (if known)				
2	WO	96/08274	A2	Prizm Pharmaceuticals, Inc.	03/21/1996		
3	WO	99/26480	A1	Genetix Pharmaceuticals, Inc. and MIT	06/03/1999		

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

JUN 11 2002

Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Attorney Docket Number 05213-0551US(43170-258385)

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>2</sup>	
	4	Author: BOEHM ET AL.  Publ: <u>Yeast</u>	Title: Disruption of the KEX1 Gene in <i>Pichia pastoris</i> Allows Expression of Full-Length Murine and Human Endostatin	Vol/Iss: 15	Pages: 563-572	Date: 1999	
	5	Author: BOEHM ET AL.  Publ: <u>Biochemical and Biophysical Research Communications</u>	Title: Zinc-Binding of Endostatin is Essential for Its Antangiogenic Activity	Vol/Iss: 252	Pages: 190-194	Date: 1998	
	6	Author: DHANABAL ET AL.  Publ: <u>Cancer Research</u>	Title: Endostatin: Yeast Production, Mutants, and Antitumor Effect in Renal Cell Carcinoma	Vol/Iss: 59	Pages: 189-197	Date: 01/01/199	
	7	Author: JOHN ET AL.  Publ: <u>Biochemistry</u>	Title: Novel Glycosylated Forms of Human Plasma Endostatin and Circulating Endostatin-Related Fragments of Collagen XV	Vol/Iss: 38 (32)	Pages: 10217-10224	Date: 08/10/199	
	8	Author: SHEPARD ET AL.  Publ: <u>Abstracts of Papers American Chemical Society</u>	Title: Purification of Recombinant Human Endostatin and Angiostatin from <i>Pichia pastoris</i> Fermentation Broth: Expanded Bed Adsorption Chromatography Method Development and Scale Up	Vol/Iss: 219 (1-2)	Pages: BIOT 212	Date: 03/26/200	
	9	Author: STANDKER et al.  Publ: <u>FEBS Letters</u>	Title: Isolation and characterization of the circulating form of human endostatin	Vol/Iss: 420	Pages: 129-133	Date: 1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.